Received Apr 15, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPVHIB | DTAP + IPV + HIB (PENTACEL) | SANOFI PASTEUR | UNK | UK196AA | IM / LA |
five doses of DTaP instead of four hence, the Pentacel served as one additional dose of DTaP, with no reported adverse event; Initial information received on 20-Mar-2026 regarding an unsolicited valid non-serious case received from a nurse. This case involves a 4 years old female patient who received five doses of diphtheria, tetanus, acellular pertussis (DTaP) instead of four hence, the acellular pertussis vaccine, haemophilus type b (HIB) vaccine, diphtheria toxoid, poliomyelitis vaccine (inactivated), tetanus toxoid (PENTACEL) served as one additional dose of DTaP, with no reported adverse event. The patient's past medical history, past drugs, vaccination(s), family history were not provided. Concomitant medication(s) included hepatitis a vaccine (HEP A), polio vaccine (POLIO) and varicella zoster vaccine (VARICELLA). On 25-Feb-2026, the patient received acellular pertussis vaccine, haemophilus type b (HIB) vaccine, diphtheria toxoid, poliomyelitis vaccine (inactivated), tetanus toxoid powder and suspension for suspension for injection strength: standard as 0.5 mL (dose 5) once intramuscular for immunization. Public health nurse administrator sought guidance following the administration of Pentacel as the fifth dose for DTaP to a patient. They noted that the patient received five doses of DTaP instead of four hence, the Pentacel served as one additional dose of DTaP, with no reported adverse event (Extra dose administered, and latency: same day) (batch: UK196AA, expiry: 31-Mar-2026). Action taken: Not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Comments: NONE
Hepatitis A; Polio; Varicella vaccine